1
|
Aoyama Y, Kono Y, Kawahara Y. Gastrointestinal: Carcinoma of the duodenal bulb with rapid growth and distant metastasis. J Gastroenterol Hepatol 2024. [PMID: 38361450 DOI: 10.1111/jgh.16502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 12/18/2023] [Accepted: 01/07/2024] [Indexed: 02/17/2024]
Affiliation(s)
- Y Aoyama
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Y Kono
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Y Kawahara
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| |
Collapse
|
2
|
White F, Bücker R, Meyer M, Jasnowski M, Yamano A, Ito S, Ferrara J, Okunishi E, Aoyama Y. The XtaLAB Synergy-ED: progress and latest results. Acta Cryst Sect A 2022. [DOI: 10.1107/s205327332209146x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
3
|
Aoki A, Yamane M, Aoyama Y. A rare case of reactive granulomatous dermatitis during COVID-19: a possible role of cephalosporine and potential mechanisms. J Eur Acad Dermatol Venereol 2022; 36:e609-e611. [PMID: 35352414 PMCID: PMC9114838 DOI: 10.1111/jdv.18119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 03/25/2022] [Indexed: 12/02/2022]
Affiliation(s)
- A Aoki
- Department of Dermatology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan
| | - M Yamane
- Department of Dermatology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan
| | - Y Aoyama
- Department of Dermatology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan
| |
Collapse
|
4
|
Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, Iwai M, Hashiguchi S, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Yoshihara S, Manabe M, Ichihara H, Mugitani A, Aoyama Y, Nakao T, Hirose A, Hino M, Ueda S, Takenaka K, Masuko T, Akashi K, Maruno T, Uchiyama S, Takamatsu S, Wada N, Morii E, Nagamori S, Motooka D, Kanai Y, Oji Y, Nakagawa T, Kijima N, Kishima H, Ikeda A, Ogino T, Shintani Y, Kubo T, Mihara E, Yusa K, Sugiyama H, Takagi J, Miyoshi E, Kumanogoh A, Hosen N. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Sci Transl Med 2022; 14:eaax7706. [PMID: 35171652 DOI: 10.1126/scitranslmed.aax7706] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Cancer-specific cell surface antigens are ideal therapeutic targets for monoclonal antibody (mAb)-based therapy. Here, we report that multiple myeloma (MM), an incurable hematological malignancy, can be specifically targeted by an mAb that recognizes a ubiquitously present protein, CD98 heavy chain (hc) (also known as SLC3A2). We screened more than 10,000 mAb clones raised against MM cells and identified R8H283, an mAb that bound MM cells but not normal hematopoietic or nonhematopoietic cells. R8H283 specifically recognized CD98hc. R8H283 did not react with monomers of CD98hc; instead, it bound CD98hc in heterodimers with a CD98 light chain (CD98lc), a complex that functions as an amino acid transporter. CD98 heterodimers were abundant on MM cells and took up amino acids for constitutive production of immunoglobulin. Although CD98 heterodimers were also present on normal leukocytes, R8H283 did not react with them. The glycoforms of CD98hc present on normal leukocytes were distinct from those present on MM cells, which may explain the lack of R8H283 reactivity to normal leukocytes. R8H283 exerted anti-MM effects without damaging normal hematopoietic cells. These findings suggested that R8H283 is a candidate for mAb-based therapies for MM. In addition, our findings showed that a cancer-specific conformational epitope in a ubiquitous protein, which cannot be identified by transcriptome or proteome analyses, can be found by extensive screening of primary human tumor samples.
Collapse
Affiliation(s)
- Kana Hasegawa
- Laboratory of Cellular Immunotherapy, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan
| | - Shunya Ikeda
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Moto Yaga
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Kouki Watanabe
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Rika Urakawa
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Akie Iehara
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Mai Iwai
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Seishin Hashiguchi
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Soyoko Morimoto
- Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Fumihiro Fujiki
- Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Hiroko Nakajima
- Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Jun Nakata
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Sumiyuki Nishida
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Akihiro Tsuboi
- Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Yoshihiro Oka
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Satoshi Yoshihara
- Department of Hematology, Hyogo College of Medicine, Hyogo 663-8501, Japan
| | - Masahiro Manabe
- Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka 545-0053, Japan
| | | | - Atsuko Mugitani
- Department of Hematology, Fuchu Hospital, Osaka 594-0076, Japan
| | - Yasutaka Aoyama
- Department of Hematology, Fuchu Hospital, Osaka 594-0076, Japan
| | - Takafumi Nakao
- Department of Hematology, Osaka City General Hospital, Osaka 534-0021, Japan
| | - Asao Hirose
- Department of Hematology and Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8586, Japan
| | - Masayuki Hino
- Department of Hematology and Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8586, Japan
| | - Shiho Ueda
- Cell Biology Laboratory, School of Pharmacy, Kindai University, Osaka 577-8502, Japan
| | - Katsuto Takenaka
- Department of Hematology, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan
| | - Takashi Masuko
- Cell Biology Laboratory, School of Pharmacy, Kindai University, Osaka 577-8502, Japan
| | - Koichi Akashi
- Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
| | - Takahiro Maruno
- Department of Biotechnology, Graduate School of Engineering, Osaka University, Osaka 565-0871, Japan
| | - Susumu Uchiyama
- Department of Biotechnology, Graduate School of Engineering, Osaka University, Osaka 565-0871, Japan
| | - Shinji Takamatsu
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Naoki Wada
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Eiichi Morii
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Shushi Nagamori
- Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan
| | - Daisuke Motooka
- Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
| | - Yoshikatsu Kanai
- Department of Bio-system Pharmacology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Yusuke Oji
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Tomoyoshi Nakagawa
- Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Noriyuki Kijima
- Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Haruhiko Kishima
- Department of Neurosurgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Atsuyo Ikeda
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Takayuki Ogino
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Yasushi Shintani
- Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Tateki Kubo
- Department of Plastic Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Emiko Mihara
- Laboratory for Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka 565-0871, Japan
| | - Kosuke Yusa
- Stem Cell Genetics, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
| | - Haruo Sugiyama
- Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Junichi Takagi
- Laboratory for Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka 565-0871, Japan
| | - Eiji Miyoshi
- Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
| | - Atsushi Kumanogoh
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.,Laboratory of Immunopathology, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan
| | - Naoki Hosen
- Laboratory of Cellular Immunotherapy, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.,Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.,Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka 565-0871, Japan
| |
Collapse
|
5
|
Yamamoto R, Saito M, Aoyama Y, Sagehashi R, Saito T, Kashima S, Koizumi A, Nara T, Numakura K, Narita S, Satoh S, Habuchi T. Protective effects of regulatory T cells in renal ischemia/reperfusion injury in mice. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01165-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Takeichi T, Honda A, Okuno Y, Kojima D, Kono M, Nakamura Y, Tohyama M, Tanaka T, Aoyama Y, Akiyama M. Sterol profiles are valuable biomarkers for phenotype expression of Conradi-Hünermann-Happle syndrome with EBP mutations. Br J Dermatol 2018; 179:1186-1188. [PMID: 29851033 DOI: 10.1111/bjd.16823] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- T Takeichi
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - A Honda
- Joint Research Center, Tokyo Medical University Ibaraki Medical Center, Ami, Japan
| | - Y Okuno
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.,Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - D Kojima
- Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - M Kono
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Y Nakamura
- Department of Pediatrics, Ichinomiya Municipal Hospital, Ichinomiya, Japan
| | - M Tohyama
- Department of Dermatology, Ehime University School of Medicine, Toon, Japan
| | - T Tanaka
- Department of Pediatrics, Kawasaki General Hospital, Kawasaki Medical School, Okayama, Japan
| | - Y Aoyama
- Department of Dermatology, Kawasaki General Hospital, Kawasaki Medical School, Okayama, Japan
| | - M Akiyama
- Department of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| |
Collapse
|
7
|
Takakuwa T, Nakane T, Ohsawa M, Nagasaki J, Aoyama Y, Nishimoto M, Hayashi Y, Kuwae Y, Hino M, Nakamae H. The First Case of Non-leukemic Sarcoma Composed of Mixed-phenotype Acute Leukemia, B/myeloid, Not Otherwise Specified. Intern Med 2018; 57:1155-1158. [PMID: 29269643 PMCID: PMC5938510 DOI: 10.2169/internalmedicine.9144-17] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Isolated sarcoma with features of mixed-phenotype acute leukemia (MPAL) is an extremely rare disease and it can be easily misdiagnosed as lymphoma or other malignancies. We herein report the case of a 61-year-old woman with non-leukemic sarcoma of the right pleura, pretracheal lymph node, and supraclavicular lymph node with features of MPAL, B/myeloid, not otherwise specified, which was first misdiagnosed as diffuse large B cell lymphoma. After performing a detailed re-examination of the biopsy specimens, few scattered eosinophilic myelocytes allowed us to reach a correct diagnosis of MPAL and the patient was thereafter successfully treated by intensified chemotherapy followed by cord blood transplantation.
Collapse
Affiliation(s)
- Teruhito Takakuwa
- Hematology, Graduate School of Medicine, Osaka City University, Japan
| | - Takahiko Nakane
- Hematology, Graduate School of Medicine, Osaka City University, Japan
| | - Masahiko Ohsawa
- Diagnostic Pathology, Graduate School of Medicine, Osaka City University, Japan
| | - Joji Nagasaki
- Hematology, Graduate School of Medicine, Osaka City University, Japan
- Department of Hematology, Seichokai Fuchu Hospital, Japan
| | | | | | - Yoshiki Hayashi
- Hematology, Graduate School of Medicine, Osaka City University, Japan
| | - Yuko Kuwae
- Diagnostic Pathology, Graduate School of Medicine, Osaka City University, Japan
| | - Masayuki Hino
- Hematology, Graduate School of Medicine, Osaka City University, Japan
| | - Hirohisa Nakamae
- Hematology, Graduate School of Medicine, Osaka City University, Japan
| |
Collapse
|
8
|
Takeichi T, Katayama C, Tanaka T, Okuno Y, Murakami N, Kono M, Sugiura K, Aoyama Y, Akiyama M. A novel IFIH1 mutation in the pincer domain underlies the clinical features of both Aicardi-Goutières and Singleton-Merten syndromes in a single patient. Br J Dermatol 2017; 178:e111-e113. [PMID: 29270977 DOI: 10.1111/bjd.15869] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- T Takeichi
- Departments of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - C Katayama
- Departments of Dermatology, Kawasaki General Hospital, Kawasaki Medical School, Okayama, Japan
| | - T Tanaka
- Pediatrics, Kawasaki General Hospital, Kawasaki Medical School, Okayama, Japan
| | - Y Okuno
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.,Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - N Murakami
- Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - M Kono
- Departments of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - K Sugiura
- Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan
| | - Y Aoyama
- Departments of Dermatology, Kawasaki General Hospital, Kawasaki Medical School, Okayama, Japan
| | - M Akiyama
- Departments of Dermatology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| |
Collapse
|
9
|
Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A. The activated conformation of integrin β 7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med 2017; 23:1436-1443. [PMID: 29106400 DOI: 10.1038/nm.4431] [Citation(s) in RCA: 93] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2017] [Accepted: 10/02/2017] [Indexed: 12/15/2022]
Abstract
Cancer-specific cell-surface antigens are ideal targets for monoclonal antibody (mAb)-based immunotherapy but are likely to have previously been identified in transcriptome or proteome analyses. Here, we show that the active conformer of an integrin can serve as a specific therapeutic target for multiple myeloma (MM). We screened >10,000 anti-MM mAb clones and identified MMG49 as an MM-specific mAb specifically recognizing a subset of integrin β7 molecules. The MMG49 epitope, in the N-terminal region of the β7 chain, is predicted to be inaccessible in the resting integrin conformer but exposed in the active conformation. Elevated expression and constitutive activation of integrin β7 conferred high MMG49 reactivity on MM cells, whereas MMG49 binding was scarcely detectable in other cell types including normal integrin β7+ lymphocytes. T cells transduced with MMG49-derived chimeric antigen receptor (CAR) exerted anti-MM effects without damaging normal hematopoietic cells. Thus, MMG49 CAR T cell therapy is promising for MM, and a receptor protein with a rare but physiologically relevant conformation can serve as a cancer immunotherapy target.
Collapse
Affiliation(s)
- Naoki Hosen
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
- WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Yukiko Matsunaga
- Laboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka, Japan
| | - Kana Hasegawa
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hiroshi Matsuno
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yuki Nakamura
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Mio Makita
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kouki Watanabe
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Mikako Yoshida
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kei Satoh
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Soyoko Morimoto
- Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Fumihiro Fujiki
- Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hiroko Nakajima
- Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Jun Nakata
- Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Sumiyuki Nishida
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Akihiro Tsuboi
- Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yoshihiro Oka
- Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
- WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
| | - Masahiro Manabe
- Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan
| | | | | | | | - Takafumi Nakao
- Department of Hematology, Osaka City General Hospital, Osaka, Japan
| | - Masayuki Hino
- Department of Hematology and Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - Ryosuke Uchibori
- Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University, Tochigi, Japan
| | - Keiya Ozawa
- Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University, Tochigi, Japan
- Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - Yoshihiro Baba
- Division of Immunology and Genome Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
| | - Seitaro Terakura
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Naoki Wada
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Eiichi Morii
- Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Junichi Nishimura
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kiyoshi Takeda
- WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
- Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), Japan
| | - Yusuke Oji
- Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Haruo Sugiyama
- Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Junichi Takagi
- Laboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Osaka, Japan
| | - Atsushi Kumanogoh
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
- WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), Japan
| |
Collapse
|
10
|
Ido K, Aoyama Y, Nagasaki J, Koh S, Ichihara H, Harada H, Kawano K, Tani Y, Matsuyama N, Hirayama F, Kohsaki M, Takaku S, Mugitani A. Pulmonary Involvement of Acute Myeloid Leukemia Mimicking Transfusion-related Acute Lung Injury. Intern Med 2017; 56:2493-2496. [PMID: 28824064 PMCID: PMC5643180 DOI: 10.2169/internalmedicine.8505-16] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Transfusion-related acute lung injury (TRALI) is defined as a new episode of acute lung injury (ALI) occurring during transfusion or within 6 hours of transfusion completion. A 66-year-old man suffering from acute myeloid leukemia developed acute respiratory distress syndrome after platelet transfusion. TRALI was diagnosed clinically, but an autopsy showed leukemic cells in diffuse pulmonary edema. Anti-human neutrophil antigen (HNA)-3a antibodies were detected in the donor serum, and the HNA-3 genotype of the patient was identified as a/a. This case was considered to represent pulmonary involvement of acute myeloid leukemia, rather than TRALI. A revision of the definition of TRALI accounting for hematological malignancies should therefore be considered.
Collapse
Affiliation(s)
- Kentaro Ido
- Department of Hematology, Fuchu Hospital, Japan
| | | | - Joji Nagasaki
- Department of Hematology, Osaka City University Graduate School of Medicine, Japan
| | - Shiro Koh
- Department of Hematology, Fuchu Hospital, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Hashimoto T, Kawakami Y, Wakabayashi H, Oda W, Hamada T, Doi H, Aoyama Y, Iwatsuki K. An unusual clinical presentation of lupus erythematosus tumidus localized on the thigh. Clin Exp Dermatol 2017; 42:638-641. [PMID: 28597962 DOI: 10.1111/ced.13147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/21/2016] [Indexed: 11/29/2022]
Abstract
A 44-year-old woman with seronegative polyarthritis presented with a 2-year history of a solitary, bluish-red, oedematous, nonscaly, annular and partially reticulated macule on her right thigh. Histopathological findings revealed perivascular and periadnexal lymphocytic infiltrate in the dermis. Alcian blue and colloidal iron stains highlighted mucinous deposit in the upper and mid dermis. Direct immunofluorescence showed a linear deposit of IgG and C3 along the basement membrane zone. Antinuclear antibody was positive at a titre of 1 : 80, with homogenous and speckled patterns. Except for its unusual localization and lack of photosensitivity, our case had the clinical and histopathological features of lupus erythematosus tumidus. These characteristics were also reminiscent of reticular erythematous mucinosis and erythema annulare centrifugum, both of which are considered to be associated with cutaneous lupus erythematosus (CLE). Hydroxychloroquine 200 mg daily led to improvement of the skin lesion. The unusual clinical presentation of our case emphasizes the heterogeneity of clinical manifestations of CLE.
Collapse
Affiliation(s)
- T Hashimoto
- Department of Dermatology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Y Kawakami
- Department of Dermatology, Okayama City Hospital, Okayama, Japan
| | - H Wakabayashi
- Department of Rheumatology, Okayama City Hospital, Okayama, Japan
| | - W Oda
- Department of Pathology, Okayama City Hospital, Okayama, Japan
| | - T Hamada
- Department of Dermatology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - H Doi
- Department of Dermatology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Y Aoyama
- Department of Dermatology, Kawasaki Hospital, Okayama, Japan
| | - K Iwatsuki
- Department of Dermatology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan
| |
Collapse
|
12
|
Shimoda Y, Sato Y, Hayashida Y, Yamazaki Y, Mizukawa Y, Nakajima K, Shiohara T, Aoyama Y. Lichen amyloidosus as a sweat gland/duct-related disorder: resolution associated with restoration of sweating disturbance. Br J Dermatol 2017; 176:1308-1315. [DOI: 10.1111/bjd.15060] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/12/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Y. Shimoda
- Department of Dermatology; Kyorin University School of Medicine; Mitaka Japan
| | - Y. Sato
- Department of Dermatology; Kyorin University School of Medicine; Mitaka Japan
| | - Y. Hayashida
- Dermatology; Kawasaki Medical School; General Medical Center; Okayama Japan
| | - Y. Yamazaki
- Department of Dermatology; Kyorin University School of Medicine; Mitaka Japan
| | - Y. Mizukawa
- Department of Dermatology; Kyorin University School of Medicine; Mitaka Japan
| | - K. Nakajima
- Department of Dermatology; Kochi University School of Medicine; Nankoku Japan
| | - T. Shiohara
- Department of Dermatology; Kyorin University School of Medicine; Mitaka Japan
| | - Y. Aoyama
- Dermatology; Kawasaki Medical School; General Medical Center; Okayama Japan
- Department of Dermatology; Kawasaki Medical School; Kurashiki Japan
| |
Collapse
|
13
|
Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, Kakihana K, Dobashi N, Sugiura I, Onishi Y, Maeda T, Imai K, Ohtake S, Miyazaki Y, Ohnishi K, Matsuo K, Naoe T. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol 2017; 92:367-374. [PMID: 28103625 DOI: 10.1002/ajh.24653] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Revised: 01/11/2017] [Accepted: 01/14/2017] [Indexed: 01/29/2023]
Abstract
This study investigated the efficacy of imatinib based therapy with intensified consolidation therapy in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) to prevent early relapse. We conducted a phase II trial of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive ALL in adults. Sixty-eight patients were included in the trial between October 2008 and December 2010. The median age was 49 years, with 28 patients >55 years of age. Sixty-five patients achieved CR (95.6%). The estimated 2-year event-free survival (EFS) and overall survival (OS) were 62.3% and 67.4%, respectively. Allogeneic stem cell transplantation (allo-SCT) at initial CR was performed in 43 patients. Thirty-five of 39 patients <55 years and 8 of 26 patients >55 years underwent allo-SCT at first CR. The 3-year OS in patients <55 years receiving allo-SCT at first CR, patients >55 years receiving allo-SCT at first CR, patients <55 years not receiving allo-SCT at first CR, and patients >55 years not receiving allo-SCT at first CR were 80.4%, 41.1%, 32.5%, and 52.0%, respectively (P = 0.058). The three-year EFS in each group was 76.7%, 53.6%, not reached, and 26.4%, respectively (P = 0.150). A high CR rate was observed with imatinib-based chemotherapy allowing allo-SCT in a high proportion of patients, particularly those <55 years. Moreover, intensified consolidation therapy reduced early relapse rates following induction therapy and resulted in improved OS and EFS rates following allo-SCT. This trial was registered with the UMIN (000001226).
Collapse
Affiliation(s)
- Shin Fujisawa
- Department of Hematology; Yokohama City University Medical Center; Yokohama Japan
| | - Shuichi Mizuta
- Department of Hematology; Fujita Health University Hospital; Toyoake Japan
| | - Hideki Akiyama
- Tokyo Metropolitan Health and Medical Treatment Corporation Tama-Hokubu Medical Center; Tokyo Japan
| | - Yasunori Ueda
- Department of Hematology/Oncology; Kurashiki Central Hospital; Kurashiki Japan
| | - Yasutaka Aoyama
- Department of Hematology; Seichokai Fuchu Hospital; Osaka Japan
| | - Yoshihiro Hatta
- Department of Hematology and Rheumatology; Nihon University School of Medicine; Tokyo Japan
| | - Kazuhiko Kakihana
- Hematology Division; Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Tokyo Japan
| | - Nobuaki Dobashi
- Division of Clinical Oncology and Hematology; Department of Internal Medicine, The Jikei University School of Medicine; Tokyo Japan
| | - Isamu Sugiura
- Division of Hematology and Oncology; Toyohashi Municipal Hospital; Toyohashi Japan
| | - Yasushi Onishi
- Department of Hematology and Rheumatology; Tohoku University Hospital; Sendai Japan
| | - Tomoya Maeda
- Department of Hemato-Oncology; Saitama Medical University International Medical Center; Hidaka Japan
| | - Kiyotoshi Imai
- Department of Hematology; Sapporo Hokuyu Hospital; Sapporo Japan
| | - Shigeki Ohtake
- Institute of Liberal Arts and Science, Kanazawa University; Kanazawa Japan
| | - Yasushi Miyazaki
- Department of Hematology; Atomic Bomb Disease Institute, Nagasaki University; Nagasaki Japan
| | - Kazunori Ohnishi
- Oncology Center, Hamamatsu University School of Medicine; Hamamatsu Japan
| | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center Research Institute; Nagoya Japan
| | - Tomoki Naoe
- National Hospital Organization Nagoya Medical Center; Nagoya Japan
| |
Collapse
|
14
|
Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials. Int J Hematol 2016; 105:485-496. [DOI: 10.1007/s12185-016-2154-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 11/16/2016] [Accepted: 11/16/2016] [Indexed: 12/16/2022]
|
15
|
Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H. Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 2016; 48:1591. [PMID: 27898077 DOI: 10.1038/ng1216-1587a] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Machida S, Onizuka M, Toyosaki M, Aoyama Y, Kawai H, Amaki J, Hara R, Ichiki A, Ogawa Y, Kawada H, Ando K. Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant 2016; 52:307-309. [PMID: 27892947 DOI: 10.1038/bmt.2016.270] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- S Machida
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - M Onizuka
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - M Toyosaki
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - Y Aoyama
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - H Kawai
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - J Amaki
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - R Hara
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - A Ichiki
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - Y Ogawa
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - H Kawada
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| | - K Ando
- Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
| |
Collapse
|
17
|
Nagasaki J, Aoyama Y, Hino M, Ido K, Ichihara H, Manabe M, Ohta T, Mugitani A. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome. Acta Haematol 2016; 137:32-39. [PMID: 27866185 DOI: 10.1159/000452732] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Accepted: 10/17/2016] [Indexed: 12/28/2022]
Abstract
BACKGROUND/AIMS A high expression of Wilms tumor 1 (WT1) mRNA occurs in most cases of acute leukemia and myelodysplastic syndrome (MDS). Although there are many reports suggesting that acute myeloid leukemia patients with high expression levels of WT1 mRNA have a relatively poor long-term survival, there are few reports addressing the relationship between WT1 levels and prognosis in MDS. METHODS We retrospectively analyzed 42 elderly patients with MDS whose WT1 levels at diagnosis were available, and we assessed the relationships between WT1 levels in peripheral blood and preexisting prognostic factors such as World Health Organization prognostic scores and Revised International Prognostic Scoring System risk categories, bone marrow blast percentages, and chromosomal abnormalities linked to a poor prognosis. We also evaluated the relationship between WT1 levels and prognosis. RESULTS WT1 levels were significantly different between high- and low-risk MDS patients (p < 0.05). There was a trend towards a significant difference between those with and those without poor prognostic chromosomal rearrangements (p = 0.051). Moreover, the overall survival and progression-free survival were significantly worse in elderly patients with higher levels of WT1 (p = 0.00039 and p = 0.00077, respectively). CONCLUSIONS The WT1 mRNA expression level at diagnosis may be a significant independent prognostic marker for elderly patients with MDS.
Collapse
Affiliation(s)
- Joji Nagasaki
- Department of Hematology, Seichokai Fuchu Hospital, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Aomatsu N, Uchima Y, Aoyama Y, Tsujio G, Wang E, Yamakoshi Y, Nagashima D, Hirakawa T, Iwauchi T, Nishii T, Nakazawa K, Tei S, Takeuchi K. [A Case of Small Intestinal Malignant Lymphoma Presenting with Perforated Peritonitis]. Gan To Kagaku Ryoho 2016; 43:1833-1835. [PMID: 28133147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
An 85-year-old man presented to the emergency department with vomiting. He had tenderness in the left abdomen and under the umbilicus. Laboratory data showed an increase in the inflammatory response. Enhanced abdominal computed tomography showed thickening ofthe small intestinal wall in the lower left abdomen with a small amount ofadjacent free air. The fat tissue around the small intestine also revealed a high density area suggestive of inflammation. A diagnosis of peritonitis caused by intestinal perforation was made and an emergency operation was performed. We resected part of the ileum about 90 cm from the ileum end. The resected specimen showed a 1 by 1 cm mass with an ulcer and perforation at the base of the tumor. Histopathological findings revealed densely increased numbers of monomorphic medium-sized lymphoma cells infiltrating into all layers ofthe intestine. Immunohistochemically, the lymphocytes were positive for CD3, CD20, CD30, and CD79a. We diagnosed diffuse large B-cell lymphoma. Two cycles ofchemotherapy were given post-operatively. A recurrence was not observed. After chemotherapy he was transferred to rehabilitation.
Collapse
MESH Headings
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Chemotherapy, Adjuvant
- Humans
- Ileal Neoplasms/complications
- Ileal Neoplasms/diagnostic imaging
- Ileal Neoplasms/drug therapy
- Ileal Neoplasms/surgery
- Intestinal Perforation/diagnostic imaging
- Intestinal Perforation/etiology
- Intestinal Perforation/surgery
- Lymphoma, Large B-Cell, Diffuse/complications
- Lymphoma, Large B-Cell, Diffuse/diagnostic imaging
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/surgery
- Male
- Peritonitis/diagnostic imaging
- Peritonitis/etiology
- Peritonitis/surgery
- Tomography, X-Ray Computed
- Treatment Outcome
Collapse
|
19
|
Takehara A, Aoyama Y, Kurosawa M, Shirafuji Y, Umemura H, Kamiya K, Ushigome Y, Kano Y, Shiohara T, Iwatsuki K. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms. Br J Dermatol 2016; 175:944-952. [DOI: 10.1111/bjd.14677] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2016] [Indexed: 12/17/2022]
Affiliation(s)
- A. Takehara
- Department of Dermatology; Okayama University Graduate School of Medicine; Dentistry and Pharmaceutical Sciences; Okayama Japan
| | - Y. Aoyama
- Department of Dermatology; Kawasaki Medical School; Kurashiki Japan
- Department of Dermatology; Kawasaki Hospital; 2-1-80 Nakasange Kitaku Okayama City Okayama 700-8505 Japan
| | - M. Kurosawa
- Department of Epidemiology and Environmental Health; Juntendo University Graduate School of Medicine; Tokyo Japan
| | - Y. Shirafuji
- Department of Dermatology; Okayama University Graduate School of Medicine; Dentistry and Pharmaceutical Sciences; Okayama Japan
| | - H. Umemura
- Department of Dermatology; Okayama University Graduate School of Medicine; Dentistry and Pharmaceutical Sciences; Okayama Japan
| | - K. Kamiya
- Department of Dermatology; Hamamatsu University School of Medicine; Hamamatsu Japan
| | - Y. Ushigome
- Department of Dermatology; Kyorin University School of Medicine; Tokyo Japan
| | - Y. Kano
- Department of Dermatology; Kyorin University School of Medicine; Tokyo Japan
| | - T. Shiohara
- Department of Dermatology; Kyorin University School of Medicine; Tokyo Japan
| | - K. Iwatsuki
- Department of Dermatology; Okayama University Graduate School of Medicine; Dentistry and Pharmaceutical Sciences; Okayama Japan
| |
Collapse
|
20
|
Nagasaki J, Aoyama Y, Nomoto Y, Ido K, Ichihara H, Mugitani A. Reversible dasatinib-related pulmonary arterial hypertension in a CML patient. Rinsho Ketsueki 2016; 57:618-23. [PMID: 27263788 DOI: 10.11406/rinketsu.57.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 59-year-old man diagnosed with the chronic phase of chronic myeloid leukemia (CML) in June 2011 was started on dasatinib (100 mg/day). He had no signs of pleural effusion (PE) or right heart failure before treatment, but symptoms of PE and dyspnea (New York Heart Association class III) appeared in January 2013 and May 2014, respectively. Doppler transthoracic echocardiography and right heart catheterization revealed pulmonary arterial hypertension (PAH) with an estimated pulmonary artery systolic pressure (PASP) of 80 mmHg and estimated mean pulmonary artery pressure of 29 mmHg. Rheumatoid factor, antinuclear antibody, dsDNA antibody, and SCL70 were not elevated, and computed tomography confirmed the absence of a pulmonary embolism. Therefore, dasatinib-related PAH was diagnosed and treatment with this agent was discontinued. The PASP had decreased to 51 and 40 mmHg at one month and one year, respectively, after dasatinib discontinuation. This patient developed PAH while receiving dasatinib administration and only discontinuation of this agent improved his symptoms. The possibility that dasatinib can cause PAH must be considered before administering this agent to patients with CML.
Collapse
|
21
|
Aoyama T, Hirata K, Yamamoto Y, Yokota H, Hayashi H, Aoyama Y, Matsumoto Y. Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis. J Clin Pharm Ther 2016; 41:392-8. [PMID: 27178380 DOI: 10.1111/jcpt.12395] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2015] [Accepted: 04/05/2016] [Indexed: 11/28/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Midazolam (MDZ) is commonly used for sedating critically ill patients. The daily dose required for adequate sedation increases in increments over 100 h after administration. The objectives of this study were to characterize the MDZ pharmacokinetics in critically ill patients and to describe the phenomenon of increasing daily dose by means of population pharmacokinetic analysis. METHODS Data were obtained from 30 patients treated in an intensive care unit. The patients received MDZ intravenously as a combination of bolus and continuous infusion. Serum MDZ concentration was assayed by high-performance liquid chromatography. Population pharmacokinetic analysis was performed using the NONMEM software package. The alteration of clearance unexplained by demographic factors and clinical laboratory data was described as an autoinduction of MDZ clearance using a semi-mechanistic pharmacokinetic-enzyme turnover model. RESULTS AND DISCUSSION The final population pharmacokinetic model was a one-compartment model estimated by incorporating a semi-mechanistic pharmacokinetic-enzyme turnover model for clearance, taking autoinduction into account. A significant covariate for MDZ clearance was total bilirubin. An increase in total bilirubin indicated a reduction in MDZ clearance. From simulation using the population pharmacokinetic parameters obtained in this study, MDZ clearance increased 2·3 times compared with pre-induced clearance 100 h after the start of 12·5 mg/h continuous infusion. WHAT IS NEW AND CONCLUSION Autoinduction and total bilirubin were significant predictors of the clearance of MDZ in this population. Step-by-step dosage adjustment using this population pharmacokinetic model may be useful for establishing a MDZ dosage regimen in critically ill patients.
Collapse
Affiliation(s)
- T Aoyama
- Laboratory of Clinical Pharmacokinetics, School of Pharmacy, Nihon University, Chiba, Japan
| | - K Hirata
- Department of Pharmacy, Fureai Higashitotsuka Hospital, Yokohama, Japan
| | - Y Yamamoto
- Department of Emergency and Critical Care Medicine, Nippon Medical School Hospital, Tokyo, Japan
| | - H Yokota
- Department of Emergency and Critical Care Medicine, Nippon Medical School Hospital, Tokyo, Japan
| | - H Hayashi
- Laboratory of Pharmacotherapy, School of Pharmacy, Nihon University, Chiba, Japan
| | - Y Aoyama
- Laboratory of Clinical Pharmacokinetics, School of Pharmacy, Nihon University, Chiba, Japan.,Second Department of Anesthesiology, Toho University School of Medicine, Tokyo, Japan
| | - Y Matsumoto
- Laboratory of Clinical Pharmacokinetics, School of Pharmacy, Nihon University, Chiba, Japan
| |
Collapse
|
22
|
Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 2016; 48:569-74. [PMID: 27019113 DOI: 10.1038/ng.3535] [Citation(s) in RCA: 173] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 03/02/2016] [Indexed: 11/09/2022]
Abstract
The oncogenic mechanisms underlying acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA; 15-39 years old) remain largely elusive. Here we have searched for new oncogenes in AYA-ALL by performing RNA-seq analysis of Philadelphia chromosome (Ph)-negative AYA-ALL specimens (n = 73) with the use of a next-generation sequencer. Interestingly, insertion of D4Z4 repeats containing the DUX4 gene into the IGH locus was frequently identified in B cell AYA-ALL, leading to a high level of expression of DUX4 protein with an aberrant C terminus. A transplantation assay in mice demonstrated that expression of DUX4-IGH in pro-B cells was capable of generating B cell leukemia in vivo. DUX4 fusions were preferentially detected in the AYA generation. Our data thus show that DUX4 can become an oncogenic driver as a result of somatic chromosomal rearrangements and that AYA-ALL may be a clinical entity distinct from ALL at other ages.
Collapse
Affiliation(s)
- Takahiko Yasuda
- Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.,Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Shinobu Tsuzuki
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan
| | - Masahito Kawazu
- Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Fumihiko Hayakawa
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Shinya Kojima
- Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Toshihide Ueno
- Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Naoto Imoto
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Shinji Kohsaka
- Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Akiko Kunita
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Koichiro Doi
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan
| | - Toru Sakura
- Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan
| | - Toshiaki Yujiri
- Third Department of Internal Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
| | - Eisei Kondo
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | | | - Yasunori Ueda
- Department of Hematology/Oncology, Kurashiki Central Hospital, Okayama, Japan
| | - Yasutaka Aoyama
- Department of Internal Medicine, Seichoukai Fuchu Hospital, Osaka, Japan
| | - Shigeki Ohtake
- Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan
| | - Junko Takita
- Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Eirin Sai
- Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Masafumi Taniwaki
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Mineo Kurokawa
- Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Shinichi Morishita
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan
| | - Masashi Fukayama
- Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Hitoshi Kiyoi
- Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan
| | - Yasushi Miyazaki
- Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
| | - Tomoki Naoe
- National Hospital Organization Nagoya Medical Center, Aichi, Japan
| | - Hiroyuki Mano
- Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
23
|
Matsuda N, Higashi T, Umino H, Makishi G, Hinoshita T, Yoshida T, Nakahara K, Shioya Y, Nishikimi M, Aoyama Y, Numaguchi A. Analysis of early goal-directed enteral nutrition in nagoya university emergency ICU. Intensive Care Med Exp 2015. [PMCID: PMC4796170 DOI: 10.1186/2197-425x-3-s1-a183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
24
|
Kim TY, Yoshimoto T, Aoyama Y, Niimi K, Takahashi E. Analysis of the protective effects of a neuronal Cav2.1 calcium channel in brain injury. Neuroscience 2015; 313:110-21. [PMID: 26616403 DOI: 10.1016/j.neuroscience.2015.11.035] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Revised: 10/30/2015] [Accepted: 11/16/2015] [Indexed: 01/13/2023]
Abstract
We previously reported that rolling Nagoya mice carrying a mutation in the α1 subunit of the Cav2.1 channel protective from ischemia- and kainate-induced neuronal damage. However, the protective effect of this mutation and its relationship to brain injury recovery have not been examined. To examine the relationship between Cav2.1 channel function and brain injury, we induced cryogenic brain damage in homozygous rolling Nagoya (rol/rol), control wild-type (+/+), ω-agatoxin IVA-pretreated +/+ (ω-aga +/+), and ω-agatoxin IVA-post-treated +/+ (ω-aga-post-treated +/+) mice. We measured the lesion area, blood brain-barrier permeability and performed immunohistochemistry and western blot analysis. The lesions of rol/rol and ω-aga +/+ mice were significantly smaller than those observed in +/+ mice at both day 1 and day 7 after injury. Similar results were shown in blood-brain barrier permeability. We observed more reactive astrogliosis in +/+ mice than in rol/rol or ω-aga +/+ mice. rol/rol and ω-aga +/+ mice had fewer degenerating cells due to cryogenic injury than did +/+ mice at both day 1 and day 7. ω-Aga-post-treated +/+ mice 24h after injury were sacrificed on day 7. The lesions were smaller in ω-aga-post-treated +/+ mice than those in vehicle-treated +/+ mice. We also examined phosphorylated p38 (pp38) at the injured site. ω-Aga-post-treated +/+ mouse brain slices showed weak pp38 signal; vehicle-treated +/+ mouse brain slices were pp38-positive. These findings demonstrate that the mutant Cav2.1 channel exerts a protective effect against cryogenic brain injury in rolling Nagoya mice. Our results indicate that inhibitors of the Cav2.1-dependent p38 signaling cascade would be useful as therapeutic agents in the treatment of brain injury.
Collapse
Affiliation(s)
- T Y Kim
- Research Resources Center, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Yoshimoto
- Research Resources Center, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Aoyama
- Research Resources Center, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Niimi
- Research Resources Center, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - E Takahashi
- Research Resources Center, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
| |
Collapse
|
25
|
Kamiya K, Aoyama Y, Yamasaki O, Kamata A, Yamagami J, Iwatsuki K, Tokura Y. Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages. Br J Dermatol 2015; 174:113-9. [DOI: 10.1111/bjd.14098] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/13/2015] [Indexed: 12/15/2022]
Affiliation(s)
- K. Kamiya
- Department of Dermatology Hamamatsu University School of Medicine 1‐20‐1 Handayama Higashi‐ku Hamamatsu 431‐3192 Japan
- Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
| | - Y. Aoyama
- Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
- Department of Dermatology Kawasaki Hospital Kawasaki Medical School Okayama Japan
| | - O. Yamasaki
- Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
| | - A. Kamata
- Department of Dermatology Keio University School of Medicine Tokyo Japan
| | - J. Yamagami
- Department of Dermatology Keio University School of Medicine Tokyo Japan
| | - K. Iwatsuki
- Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
| | - Y. Tokura
- Department of Dermatology Hamamatsu University School of Medicine 1‐20‐1 Handayama Higashi‐ku Hamamatsu 431‐3192 Japan
| |
Collapse
|
26
|
Ae R, Kojo T, Tsuboi S, Aoyama Y, Kotani K, Takamura H, Tsogzolbaatar EO, Yamada M, Mizusawa H, Nakamura Y. Epidemiologic Features of Human Prion Diseases in Japan: A Prospective 14-year Surveillance. Int J Epidemiol 2015. [DOI: 10.1093/ije/dyv096.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Tsuboi S, Kotani K, Aoyama Y, Ae R, Kojo T, Tsogzolbaatar EO, Takamura H, Nakamura Y. A Disease Map of Male Suicide in Japan and its Association with Socioeconomic Factors. Int J Epidemiol 2015. [DOI: 10.1093/ije/dyv096.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Nagano H, Yokoyama H, Hashimoto H, Watanabe M, Nakanishi M, Aoyama Y, Kawasaki T, Kishida Y, Katou M, Shimo T, Ishizuka K. EP-1228: Separated arc vs. single arc VMAT therapy for the prostate in the prone position. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)41220-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Miyake T, Yamamoto T, Hirai Y, Otsuka M, Hamada T, Tsuji K, Morizane S, Suzuki D, Aoyama Y, Iwatsuki K. Survival rates and prognostic factors of Epstein-Barr virus-associated hydroa vacciniforme and hypersensitivity to mosquito bites. Br J Dermatol 2014; 172:56-63. [DOI: 10.1111/bjd.13411] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/15/2014] [Indexed: 11/28/2022]
Affiliation(s)
- T. Miyake
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - T. Yamamoto
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
- Department of Dermatology; Kawasaki Medical School; Okayama Japan
| | - Y. Hirai
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - M. Otsuka
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - T. Hamada
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - K. Tsuji
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - S. Morizane
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - D. Suzuki
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - Y. Aoyama
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| | - K. Iwatsuki
- Department of Dermatology; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 2-5-1 Shikata-cho Kita-ku Okayama 700-8558 Japan
| |
Collapse
|
30
|
Aoyama Y, Manabe M, Kumura T, Harada N, Nagasaki J, Ohkita J, Mugitani A. Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients with Aml or High Risk Mds. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu435.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Manabe M, Dozaiku T, Okita J, Nagasaki J, Harada N, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A. Diffuse Large B-Cell Lymphoma During Azathioprine Therapy for Autoimmune Hepatitis: a Case Report. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu436.98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Kurata M, Mizukawa Y, Aoyama Y, Shiohara T. Herpes simplex virus reactivation as a trigger of mucous lesions in pemphigus vulgaris. Br J Dermatol 2014; 171:554-60. [DOI: 10.1111/bjd.12961] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2014] [Indexed: 12/31/2022]
Affiliation(s)
- M. Kurata
- Department of Dermatology Kyorin University School of Medicine Shinkawa, 6‐20‐2 Mitaka Tokyo 181‐8611 Japan
| | - Y. Mizukawa
- Department of Dermatology Kyorin University School of Medicine Shinkawa, 6‐20‐2 Mitaka Tokyo 181‐8611 Japan
| | - Y. Aoyama
- Department of Dermatology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama 700‐8558 Japan
| | - T. Shiohara
- Department of Dermatology Kyorin University School of Medicine Shinkawa, 6‐20‐2 Mitaka Tokyo 181‐8611 Japan
| |
Collapse
|
33
|
Morii K, Nishisaka M, Nakamura S, Oda T, Aoyama Y, Yamamoto T, Kishida H, Okushin H, Uesaka K. A case of synthetic oestrogen-induced autoimmune hepatitis with microvesicular steatosis. J Clin Pharm Ther 2014; 39:573-6. [DOI: 10.1111/jcpt.12191] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2014] [Accepted: 06/16/2014] [Indexed: 12/23/2022]
Affiliation(s)
- K. Morii
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| | - M. Nishisaka
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| | - S. Nakamura
- Department of Gastroenterology and Hepatology; Okayama University Hospital; Okayama Japan
| | - T. Oda
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| | - Y. Aoyama
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| | - T. Yamamoto
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| | - H. Kishida
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| | - H. Okushin
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| | - K. Uesaka
- Department of Hepatology; Japanese Red Cross Society Himeji Hospital; Himeji Hyogo Japan
| |
Collapse
|
34
|
Manabe M, Okita J, Takakuwa T, Harada N, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A. [Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report]. Gan To Kagaku Ryoho 2014; 41:781-784. [PMID: 25129095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A 7 1-year-old man was admitted to our hospital with leukocytosis and anemia. Chronic myelomonocytic leukemia (CMML)harboring del(20q)was diagnosed by peripheral blood examination and bone marrow aspiration. The patient was subsequently treated with azacitidine, which resulted in rapid disappearance of monocytosis and resolved his dependency on red cell transfusion. With regard to the chromosomal abnormality, although del(20q)is estimated to be encountered in approximately 0.7-1.0% of all CMML cases, its significance in prognosis has not been fully analyzed. Hence, more such cases need to be evaluated to elucidate the therapeutic outcome of CMML involving del(20q). In addition, the Wilms tumor-1(WT 1)level in the patient gradually decreased after the initiation of azacitidine therapy. This phenomenon of WT1 decrease synchronizing with the patient's clinical improvement might reflect therapeutic efficacy with regard to the clinical course, as had been observed in acute myeloid leukemia and myelodysplastic syndrome.
Collapse
|
35
|
Matsuoka D, Manabe M, Okita J, Takakuwa T, Harada N, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A. [Neutropenic enterocolitis after autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma - a case report]. Gan To Kagaku Ryoho 2014; 41:513-515. [PMID: 24743372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Here we report a case of a 59-year-old man who developed neutropenic enterocolitis(NE)after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma in his second complete remission.Four days after transplantation, the patient suffered from diarrhea, abdominal pain, fever, and paralytic ileus.Abdominal computerized tomography scan revealed bowel wall thickening consistent with NE.Owing to his poor performance status, only medical management, including antibiotics and bowel rest, was administered, and the patient died 18 days after transplantation.Although NE after autologous peripheral blood stem cell transplantation is a relatively rare complication, it is important to be aware that this condition can occur as one of the early complications in stem cell transplantation.
Collapse
|
36
|
Manabe M, Okita J, Tarakuwa T, Harada N, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A. der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. Acta Haematol 2014; 132:134-9. [PMID: 24556628 DOI: 10.1159/000357111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Accepted: 10/29/2013] [Indexed: 01/22/2023]
Abstract
We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p. Although deletions of 5q and 17p are recurrent abnormalities in hematological disease, only about 20 cases harboring der(5; 17) (p10;q10) have been reported. We address the tumorigenesis and morphological characteristics of hematological malignancies involving der(5; 17)(p10;q10), along with a review of the literature.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Anemia, Refractory, with Excess of Blasts/drug therapy
- Anemia, Refractory, with Excess of Blasts/genetics
- Anemia, Refractory, with Excess of Blasts/pathology
- Aneuploidy
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bone Marrow Cells/ultrastructure
- Cell Transformation, Neoplastic/genetics
- Chromosome Aberrations
- Chromosome Banding
- Chromosomes, Human, Pair 17/ultrastructure
- Chromosomes, Human, Pair 5/ultrastructure
- Contraindications
- Fatal Outcome
- Female
- Hematologic Neoplasms/genetics
- Hematologic Neoplasms/pathology
- Humans
- Karyotype
- Lenalidomide
- Leukemia, Myelomonocytic, Chronic/genetics
- Leukemia, Myelomonocytic, Chronic/pathology
- Lymphoma, T-Cell, Peripheral/drug therapy
- Male
- Megakaryocytes/ultrastructure
- Myelodysplastic Syndromes/genetics
- Myelodysplastic Syndromes/pathology
- Neoplasms, Second Primary/genetics
- Neoplasms, Second Primary/pathology
- Recurrence
- Remission Induction
- Thalidomide/analogs & derivatives
- Translocation, Genetic
Collapse
|
37
|
Nagano H, Yokoyama H, Hashimoto H, Watanabe M, Nakanishi M, Aoyama Y, Kishida Y, Onishi T. EP-1556: Separated partial arc VMAT compared with single full or angled partial arc VMAT for the prostate carcinoma. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31674-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
38
|
Hatanaka S, Ichihara H, Aoyama Y, Koh S, Yamamura R, Kumura T, Kosaka S, Inaba A, Ohta K, Mugitani A. [Usefulness of measuring serum procalcitonin levels by immunochromatographic assay in febrile neutropenia]. Rinsho Ketsueki 2014; 55:105-109. [PMID: 24492027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
In order to clarify the usefulness of measuring procalcitonin (PCT) values under the extreme condition called febrile neutropenia (FN), PCT was measured with immunochromatographic assay (ICA) and electro-chemi-luminescence immunoassay (ECLIA) at two time points: upon FN occurrence and 12 to 24 hours after FN occurrence, and correlations and associations between the two methods were reviewed. A strong correlation between the ICA and ECLIA results was observed when Spearman's rank correlation coefficient was 0.878, and the association was also demonstrated by Fisher's direct test since P=4.68×10(-10). Special equipment is not required, the operations are simple, and the ICA method currently adopted by many facilities can be used as the standard method even for the clinical condition known as FN.
Collapse
|
39
|
Manabe M, Nishii T, Okita J, Nagasaki J, Harada N, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Takeuchi K, Mugitani A. Chronic myelogenous leukemia after postoperative adjuvant S-1 therapy for rectal cancer: a case report. Am J Blood Res 2013; 3:286-289. [PMID: 24396706 PMCID: PMC3875274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 11/28/2013] [Accepted: 12/12/2013] [Indexed: 06/03/2023]
Abstract
We report a case in which chronic myelogenous leukemia (CML) developed after postoperative adjuvant S-1 therapy for rectal cancer. A 56-year-old man was diagnosed with rectal adenocarcinoma, which was treated with abdominoperineal resection followed by a year of adjuvant S-1 therapy. At 39 postoperative months, he was diagnosed with CML. Although it remains unclear that CML that develops after treatment involving cytotoxic agents is treatment-related, clinicians should be aware of the possibility of CML developing after S-1 therapy.
Collapse
Affiliation(s)
- Masahiro Manabe
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Takafumi Nishii
- Department of Surgery, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Junya Okita
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Johji Nagasaki
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Naonori Harada
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Yasutaka Aoyama
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Takeo Kumura
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Tadanobu Ohta
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Yoshio Furukawa
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Kazuhiro Takeuchi
- Department of Surgery, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Atsuko Mugitani
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| |
Collapse
|
40
|
Manabe M, Okita J, Harada N, Takakuwa T, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A. Reciprocal T(7;11)(P15;P15): A Rare but Recurrent Translocation in Acute Myeloid Leukemia. Report of 3 Cases. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.94] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Ono S, Tanioka M, Tanizaki H, Fujisawa A, Koga H, Hashimoto T, Kamiya K, Aoyama Y, Iwatsuki K, Miyachi Y. Concurrence of autoantibodies to bullous pemphigoid antigens and desmoglein 3: analysis of pathogenic and nonpathogenic antibodies. Br J Dermatol 2013; 168:1357-60. [PMID: 23738642 DOI: 10.1111/bjd.12143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Manabe M, Takeda O, Okita J, Takakuwa T, Harada N, Nakano H, Okamoto S, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A. A rare der(Y)t(Y;1)(q12;q12) in a patient with post-polycythemic myelofibrosis: a case report. Am J Blood Res 2013; 3:186-190. [PMID: 23675569 PMCID: PMC3649809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Accepted: 03/29/2013] [Indexed: 06/02/2023]
Abstract
We describe a case of post-polycythemic myelofibrosis harboring der(Y)t(Y;1)(q12;q12). The patient was a 69-year-old man and was initially diagnosed with polycythemia vera. During the clinical course of his condition, the polycythemia developed into myelofibrosis. Chromosome analysis detected der(Y)t(Y;1)(q12;q12). We discuss the association between der(Y)t(Y;1)(q11~12;q12~21) and tumorigenesis along with a review of literature.
Collapse
Affiliation(s)
- Masahiro Manabe
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Osami Takeda
- Department of Gastroenterology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Junya Okita
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Teruhito Takakuwa
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Naonori Harada
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Hirofumi Nakano
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Shuichiro Okamoto
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Yasutaka Aoyama
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Takeo Kumura
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Tadanobu Ohta
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Yoshio Furukawa
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| | - Atsuko Mugitani
- Department of Hematology, Seichokai Fuchu Hospital1–10–17 Hiko–cho, Izumi, Osaka 594–0076, Japan
| |
Collapse
|
43
|
Manabe M, Takakuwa T, Nakano H, Harada N, Okamoto S, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Matsuda M, Mugitani A. Derivative (5;19)(p10;q10): a rare but recurrent whole-arm translocation in acute myeloid leukemia. Asia Pac J Clin Oncol 2013; 10:e122-6. [PMID: 23279927 DOI: 10.1111/ajco.12051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2012] [Indexed: 12/14/2022]
Abstract
A previous study of cases of myelodysplastic syndrome harboring der(5;19)(p10;q10) found that they displayed common characteristics including predominance in elderly men, dysplasia involving three hematopoietic lineages and CD7 expression in blasts. However, the whole-arm translocation der(5;19)(p10;q10) has not been fully analyzed because of its rarity. In this study we used flow cytometry to evaluate the immunophenotype of two patients' bone marrow mononuclear cells. Both patients had involved der(5;19)(p10;q10) in their karyotype analyzed by standard G-banding technique. Both patients had the CD7+ and CD41+ phenotype, and the CD41 positivity suggested that the myeloid neoplasms involving der(5;19)(p10;q10) were of megakaryoblastic origin. The der(5;19)(p10;q10) abnormality is associated with unique characteristics of the immunophenotype. We address the clinical, immunophenotypic and morphological aspects of hematological malignancy involving der(5;19)(p10;q10), along with a review of the literature.
Collapse
Affiliation(s)
- Masahiro Manabe
- Department of Hematology, Seichokai Fuchu Hospital, Izumi, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Nakamura S, Asai H, Akita S, Aoyama Y, Kamikubo Y, Sugama Y, Takei H, Nishio T, Maruyama K, Hayakawa K. Development of Fast and High-spatial-resolution 3-dimensional Dosimetry Equipment for Both the Narrow Beam and the Broad Beam in Proton Therapy. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Manabe M, Nishii T, Harada N, Nakano H, Takakuwa T, Okamoto S, Aoyama Y, Kumura T, Mugitani A. Chronic Myelogenous Leukaemia Following S-1 THerapy for Rectal Cancer: A Case report. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32533-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
46
|
Nishimura K, Tanaka T, Tsubuku T, Matono S, Nagano T, Murata K, Aoyama Y, Yanagawa T, Shirouzu K, Fujita H. Reflux esophagitis after esophagectomy: impact of duodenogastroesophageal reflux. Dis Esophagus 2012; 25:381-5. [PMID: 21967617 DOI: 10.1111/j.1442-2050.2011.01268.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Reflux esophagitis (RE) is a known complication disturbing patients' quality of life after esophageal resection. It is generally recognized that bile reflux as well as acid reflux cause RE. However, the clinical influence of acid and bile reflux, and Helicobacter pylori (H. pylori) infection on RE in the cervical esophagus after esophagectomy is not yet clarified. Sixty patients who underwent cervical esophagogastrostomy following esophagectomy were enrolled in this study. They underwent examination for H. pylori infection, endoscopic examination, and continuous 24-hour pH and bilirubin monitoring, at 1 month after surgery. The influence of acid and/or bile reflux, H. pylori infection, and others on the development of RE were investigated. RE was observed in 19 patients (32%) at 1 month after esophagogastrostomy, mild RE in 16 (27%), and severe RE in 3 (5%). The percentage of time duration of both acid and bile reflux into the cervical esophagus was higher in patients with RE than in those without (P = 0.027, P < 0.001). A significant difference in %time pH < 4 acid reflux was found between mild RE and severe RE (P = 0.014), and a statistical difference in %time abs. > 0.14 between non-RE and mild RE (P = 0.017). Acid and/or bile reflux was observed in 31 patients (52%), acid-only reflux in 6 (10%), bile-only reflux in 15 (25%), and acid-and-bile reflux in 10 (17%). Severe RE was observed only in patients having acid-and-bile reflux. On the univariate analysis, no infection of H. pylori, acid reflux, and bile reflux were determined to be the influencing factors to RE among the clinical factors including age, gender, route of esophageal reconstruction, H. pylori infection, and acid-and-bile reflux. In the subanalysis using the logistic model, there were significant correlations between bile reflux and RE irrespective of the presence of H. pylori infection (P = 0.016, P = 0.007). On the other hand, there was a significant correlation between acid reflux and RE only in patients without H. pylori infection (P = 0.039). In the early period after esophagogastrostomy, bile reflux could cause RE irrespective of H. pylori infection, while acid reflex could cause RE only in patients without H. pylori infection. There is a possibility that bile reflux plays an important role in the development of RE after esophagectomy.
Collapse
Affiliation(s)
- K Nishimura
- Department of Surgery Biostatistics Center, Kurume University, Kurume, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Kamiya K, Aoyama Y, Shirafuji Y, Hamada T, Morizane S, Fujii K, Hisata K, Iwatsuki K. Detection of antibodies against the non-calcium-dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic significance. Br J Dermatol 2012; 167:252-61. [PMID: 22404487 DOI: 10.1111/j.1365-2133.2012.10929.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Antidesmoglein (anti-Dsg) 3 serum antibody titres are usually correlated with the disease activity of pemphigus vulgaris (PV), but some patients retain high titres even in remission. OBJECTIVES The aim of our study was to determine whether anti-Dsg3 antibodies in PV sera recognized calcium (Ca(2+) )-dependent or non-Ca(2+) -dependent epitopes, and to evaluate their pathogenicity. METHODS Dsg3 baculoprotein-coated enzyme-linked immunosorbent assay (ELISA) plates were treated with 0.5 mmol L(-1) ethylenediaminetetraacetic acid (EDTA). The binding ability of anti-Dsg3 monoclonal antibodies (mAbs) was analysed. Eight of the 83 patients with PV who were screened had elevated Dsg3 ELISA index values > 00 in remission. The binding ability of these PV sera was analysed. We evaluated the pathogenicity of anti-Dsg3 serum antibodies against the non-Ca(2+) -dependent epitopes using a dissociation assay. RESULTS The reactivity of pathogenic anti-Dsg3 mAbs against the Ca(2+) -dependent epitopes diminished markedly in the EDTA-treated ELISA, whereas no such reduction was observed in mAbs against the non-Ca(2+) -dependent epitopes. The sera of all the patients contained antibodies against both Ca(2+) -dependent and non-Ca(2+) -dependent epitopes. In six out of the eight patients, the ratio of antibodies against Ca(2+) -dependent to non-Ca(2+) -dependent epitopes decreased in remission. EDTA-treated Dsg3 baculoproteins adsorbed anti-Dsg3 serum antibodies against the non-Ca(2+) -dependent epitopes, but the remnant PV antibodies retained the ability to induce acantholysis in the dissociation assay. CONCLUSIONS We have established an assay to measure indirectly the titres of anti-Dsg3 serum antibodies against the Ca(2+) -dependent epitopes, based on the differences between EDTA-untreated and EDTA-treated ELISA index values, as a routine laboratory test to reflect the pathogenic anti-Dsg3 serum antibody titres more accurately.
Collapse
Affiliation(s)
- K Kamiya
- Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama 700-8558, Japan
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Koseki T, Mouri A, Mamiya T, Aoyama Y, Toriumi K, Suzuki S, Nakajima A, Yamada T, Nagai T, Nabeshima T. [JSNP Excellent Presentation Award for AsCNP 2011: enriched environment in adolescence prevents abnormal behavior associated with histone deacetylation in phencyclidine-treated mice]. Nihon Shinkei Seishin Yakurigaku Zasshi 2012; 32:87-89. [PMID: 22708261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
49
|
Ichihara H, Koh S, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Terada Y, Yamane T, Hino M, Mugitani A. [Complication of pernicious anemia during interferon-β treatment for type C chronic hepatitis]. Rinsho Ketsueki 2012; 53:352-356. [PMID: 22499054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A 62-year-old man with chronic hepatitis C underwent interferon (IFN)-β therapy. After treatment for a period comprising 29 months and 2 weeks, hematological results showed a decrease in white blood cell, hemoglobin, and platelet counts (WBC 2,300/µl, Hb 7.2 g/dl, PLT 4.7×10(4)/µl), and IFN therapy was stopped. Despite therapy discontinuation, the pancytopenia continued to progress with elevation of LDH (LDH 4,898 IU/l), and the patient was admitted to our hospital with suspected hematological disease. The patient underwent clinical screening, and pernicious anemia caused by vitamin B12 deficiency was diagnosed. The anemia rapidly improved with vitamin B12 treatment. Interferon is the mainstay of treatment for patients with viral hepatitis. While the adverse effects of interferon therapy are widely recognized, only a few reports have documented pernicious anemia developing during IFN-therapy. We recommend that particular attention be paid to such clinical and laboratory conditions as megaloblastic anemia when administering IFN. We also recommend checking the vitamin B12 level, as a deficiency of this vitamin may lead to the development of megaloblastic anemia.
Collapse
|
50
|
Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, Matsuoka Y, Nakajima H, Kawakami M, Yamagami T, Fuji S, Tamaki H, Nakao T, Nishida S, Tsuboi A, Iida S, Hino M, Oka Y, Oji Y, Sugiyama H. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br J Haematol 2011; 156:213-24. [PMID: 22098460 DOI: 10.1111/j.1365-2141.2011.08941.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Monoclonal antibody (mAb) drugs are desirable for the improvement of multiple myeloma (MM) treatment. In this study, we found for the first time that CD48 was highly expressed on MM plasma cells. In 22 out of 24 MM patients, CD48 was expressed on more than 90% of MM plasma cells at significantly higher levels than it was on normal lymphocytes and monocytes. CD48 was only weakly expressed on some CD34(+) haematopoietic stem/progenitor cells, and not expressed on erythrocytes or platelets. We next examined whether CD48 could serve as a target antigen for mAb therapy against MM. A newly generated in-house anti-CD48 mAb induced mild antibody-dependent cell-mediated cytotoxicity and marked complement-dependent cytotoxicity against not only MM cell lines but also primary MM plasma cells in vitro. Administration of the anti-CD48 mAb significantly inhibited tumour growth in severe combined immunodeficient mice inoculated subcutaneously with MM cells. Furthermore, anti-CD48 mAb treatment inhibited growth of MM cells transplanted directly into murine bone marrow. Finally and importantly, we demonstrated that the anti-CD48 mAb did not damage normal CD34(+) haematopoietic stem/progenitor cells. These results suggest that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against MM.
Collapse
Affiliation(s)
- Naoki Hosen
- Department of Cancer Stem Cell Biology Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|